Minor changes in effective half-life during fractionated ¹⁷⁷Lu-Octreotate therapy

References

• Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, . [177Lu-DOTAOTyr3]octreotate: Comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med 2001;28:1319–25.
   PubMedGoogle Scholar
• Barone R, Borson-Chazot F, Valkema R, Walrand S, Chauvin F, Gogou L, . Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005;46(Suppl 1):99S–106S.
   PubMed Web of Science ®Google Scholar
• Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, . Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991;21:109–22.
   PubMed Web of Science ®Google Scholar
• Sandstrom M, Garske U, Granberg D, Sundin A, Lundqvist H. Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate. Eur J Nucl Med Mol Imaging 2010;37:212–25.
   PubMed Web of Science ®Google Scholar
• Bodei L, Cremonesi M, Grana C, Rocca P, Bartolomei M, Chinol M, . Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31: 1038–46.
   PubMed Web of Science ®Google Scholar
• Cremonesi M, Botta F, Di Dia A, Ferrari M, Bodei L, De Cicco C, . Dosimetry for treatment with radiolabelled somatostatin analogues. A review. Q J Nucl Med Mol Imaging 2010;54:37–51.
   PubMed Web of Science ®Google Scholar
• Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, . MIRD pamphlet No. 20: The effect of model assumptions on kidney dosimetry and response – implications for radionuclide therapy. J Nucl Med 2008;49:1884–99.
   PubMed Web of Science ®Google Scholar
• Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 2010;37:1018–31.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, . Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005; 23:2754–62.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, . Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008;26: 2124–30.
   PubMed Web of Science ®Google Scholar
• Dieudonne A, Hobbs RF, Bolch WE, Sgouros G, Gardin I. Fine-resolution voxel S values for constructing absorbed dose distributions at variable voxel size. J Nucl Med 2010;51: 1600–7.
   PubMed Web of Science ®Google Scholar
• Ljungberg M, Frey E, Sjogreen K, Liu X, Dewaraja Y, Strand SE. 3D absorbed dose calculations based on SPECT: Evaluation for 111-In/90-Y therapy using Monte Carlo simulations. Cancer Biother Radiopharm 2003;18: 99–107.
   PubMed Web of Science ®Google Scholar
• Wilderman SJ, Dewaraja YK. Method for fast CT/SPECT-Based 3D Monte Carlo absorbed dose computations in internal emitter therapy. IEEE Trans Nucl Sci 2007;54: 146–51.
   PubMed Web of Science ®Google Scholar
• Ljungberg M, Sjögren-Gleisner K. The accuracy of absorbed dose estimates in tumours determined by quantitative SPECT: a Monte Carlo study. Acta Oncol 2011 Aug;50: 981–9.
   PubMed Web of Science ®Google Scholar
• S.Y.F. Chu LPEaRBF [Internet]. The Lund/LBNL Nuclear Data Search. 1999 [cited 2011 Aug 23]. Available from: http://nucleardata.nuclear.lu.se/nucleardata/toi/
   Google Scholar
• Helisch A, Forster GJ, Reber H, Buchholz HG, Arnold R, Goke B, . Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2004;31:1386–92.
   PubMed Web of Science ®Google Scholar
• Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: A review of validation studies on tumour assessment. Eur J Cancer 2006;42:1031–9.
   PubMed Web of Science ®Google Scholar
• Flux G, Bardies M, Chiesa C, Monsieurs M, Savolainen S, Strand SE, . Clinical radionuclide therapy dosimetry: The quest for the “Holy Gray”. Eur J Nucl Med Mol Imaging 2007;34:1699–700.
   PubMedGoogle Scholar
• Behr TM, Sharkey RM, Juweid ME, Blumenthal RD, Dunn RM, Griffiths GL, . Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res 1995;55: 3825–34.
   PubMed Web of Science ®Google Scholar
• Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9–15.
   PubMed Web of Science ®Google Scholar
• Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, . 86Y-DOTA0)-D-Phe1-Tyr3-octreotide (SMT487) – a phase 1 clinical study: Pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30:510–8.
   PubMed Web of Science ®Google Scholar
• Valkema R, Pauwels SA, Kvols LK, Kwekkeboom DJ, Jamar F, de Jong M, . Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate. J Nucl Med 2005;46(Suppl 1):83S–91S.
   Google Scholar
• Konijnenberg M, Melis M, Valkema R, Krenning E, de Jong M. Radiation dose distribution in human kidneys by octreotides in peptide receptor radionuclide therapy. J Nucl Med 2007;48:134–42.
   PubMed Web of Science ®Google Scholar